Grünenthal has received Orphan Drug and Rare Pediatric Disease designations from the US Food and Drug Administration for ...
At Binghamton University, researchers were among the first to find ways to help patients with Duchenne muscular dystrophy ...
Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from ...
Werner is CEO of Alltrna and CEO-partner at Flagship Pioneering. Duchenne muscular dystrophy has seen more progress in the past 15 months (give or take) than in the last couple of decades combined. In ...
The Food and Drug Administration (FDA) has approved the first gene therapy for the treatment of Duchenne muscular dystrophy (DMD) in children from age 4 through 5 years of age. Pediatric patients who ...
Myotonic dystrophy is thought to be caused by the binding of a protein called Mbnl1 to abnormal RNA repeats. In these two images of the same muscle precursor cell, the top image shows the location of ...
TOKYO--(BUSINESS WIRE)--Duchenne Muscular Dystrophy (DMD) patients showed signs of disease progress slowing down, after oral consumption of Neu REFIX ß-glucan for 45 days along with routine ...
Key milestones have been met in a clinical trial testing a one-time treatment that aims to turn off the faulty gene in FSHD, ...
New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...
US FDA grants orphan drug and rare paediatric disease designations to Grünenthal’s tegacorat to treat Duchenne muscular dystrophy: Aachen, Germany Thursday, July 9, 2026, 18:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results